Follow
CAR-T cell therapy
Chimeric antigen receptor (CAR) T cell therapy is a form of T cell engineering where T cells are obtained from a patient and engineered in a laboratory to better kill the patient's cancer cells. Specifically, CAR T cells are modified to express a receptor on their surface that recognizes the specific antigen present on the patient's cancer cells.
OCT 15, 2025 | 6:30 AM
Digital PCR (dPCR) is an excellent tool for rare target analysis applications because, unlike traditional PCR methods, dPCR divides samples into thousands of individual microreactions, then...
OCT 02, 2025 | 8:00 AM
CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to iso...
JUN 18, 2024 | 9:00 AM
Introduction to Magnetic Bead: Understand the history, development, versatility, and impact of Dynabeads magnetic beads: After listening to the podcast, learners will be able to explain the...
JUN 04, 2024 | 8:45 AM
Cancer immunotherapy approaches such as adoptive transfer of chimeric antigen receptor (CAR) T cells or tumor-infiltrating lymphocytes have yielded promising results in hematological maligna...
APR 30, 2024 | 1:00 PM
Chimeric antigen receptor (CAR) T-cell therapy shows significant potential in treating various human cancers. Unfortunately, researchers have faced difficulty in adapting this therapy to tar...
APR 30, 2024 | 12:00 PM
Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel therapeutic option for cancer patients in recent years. Despite its success, this approach faces acknowledged limitation...
APR 30, 2024 | 10:30 AM
C.E. CREDITS
Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieve a durable complete response. Furthermore,...
APR 30, 2024 | 7:30 AM
C.E. CREDITS
Chimeric antigen receptor (CAR) T-cell therapy has been extremely successful in treating relapsed/refractory B-cell malignancies, with six CAR T-cell products now FDA approved. Unfortunately...
On Demand
C.E. CREDITS
The study of a single cell, the fundamental unit of our complex bodies, has become an important field in cellular biology, and researchers are using single-cell analysis to shed new light on...
NOV 07, 2023 | 10:00 AM
In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART19) products for relapsed/refractory B cell lymphomas and leukemia. Ho...
NOV 01, 2023 | 10:30 AM
With the fast progress and deeper understanding of CAR-T cell therapy, finding a better solution other than lentivirus transduction is more requested, to overcome the functional limitation o...
